In February of 2011, the results of a Phase I rectal effluent study that was conducted at West Coast Clinical Trials were published in this article:
“Comparison of Dietary Phosphate Absorption After Single Doses of Lanthanum Carbonate and Sevelamer Carbonate in Healthy Volunteers: A Balance Study” in the American Journal of Kidney Disease
Lanthanum carbonate and sevelamer carbonate are noncalcium phosphate binders used to treat hyperphosphatemia in patients with chronic kidney disease. This is the first study to compare phosphate absorption from a standardized meal ingested with a typical clinical dose of these binders. The study demonstrated that in healthy volunteers, 1,000 mg of lanthanum carbonate decreased phosphate absorption by 45% compared with a 21% decrease with 2,400 mg of sevelamer carbonate.
Jon Rojas, COO, commented that “the execution of a technically difficult protocol such as collecting rectal fluid demonstrates WCCT’s ability to perform complex procedures in a skilled fashion.”
About West Coast Clinical Trials, LLC:
WCCT is a privately owned independent Phase I-IV CRO, conveniently located near 3 major airports in Southern California. Conducting trials since 1998, WCCT has been audited by the FDA and numerous pharmaceutical and biotechnology companies. WCCT’s location and access to an ethnically diverse population allows for a wide variety of study designs including ethnic bridging. With 150 beds in two locations and over 40,000 square feet, a well-trained and experienced staff, and advanced technological procedures, WCCT brings the highest quality to the pharmaceutical and biotechnology industries.
About Shire Pharmaceuticals:
As one of the world’s leading specialty biopharmaceutical companies, Shire has emerged as a company fully focused on a single purpose: to enable people with life-altering conditions to lead better lives. Shire is a global company with offices in the major pharmaceutical markets. Its UK offices are in Basingstoke and its US offices are in Wayne, Pennsylvania.